glp 1 and mental health Glucagon-like peptide-1 medicines in neurological psychiatric disorders People with pre-existing depression or

Despite its glucose mobilising effect, the broad catabolic and thermogenic nature of glucagon receptor agonism adds to its attractive portfolio as a weight loss therapeutic

Today, however, the scientific community acknowledges its multifactorial naturedriven by genetics, environment, behavior, and neuroendocrine regulationwhich has opened the door to targeted pharmacological solutions

Several trials are expected to release data in 2025, with additional studies running into 2027

Since then, the popularity of similar weight-loss medications has surged, though supply and price are often barriers to treatment

Patients interested in learning more about DietsMD.coms doctor-guided GLP-1 weight loss programs can visit to begin an online assessment and explore available treatment options